Protocol Summary

Protocol No.

131027 (FORESEE)

Principal Investigator

Buys, Saundra

Phase

N/A

Age Group

Adult

ClinicalTrials.Gov

NCT04450706 (Click to jump to clinicaltrials.gov)

Eligibility Detail

Contact

Title

FORESEE: Functional precision oncology for metastatic breast cancer: a feasibility trial

Objective

Primary Objective


<ul>
<li>To assess the feasibility of comprehensive genomic characterization and drug screening for metastatic breast cancer in a clinically relevant timeframe.</li>
</ul>


Secondary Objective(s)


<ul>
<li>To assess the time required to return genomic characterization and drug screening results to treating physicians.</li>
<li>To assess the performance and concordance of our integrated functional genomic assays (drug screen with or without genomic characterization) against commercially available assays.</li>
</ul>


Exploratory Objective(s)


<ul>
<li>To assess the clinical efficacy of treatment decisions informed by functional genomic assays compared with treatment decisions not informed by functional genomic assays.</li>
<li>To explore the effect that drug screening and genomic results have on physician treatment selection.</li>
</ul>

Applicable Disease Sites

Breast

Participating Institutions

Huntsman Cancer Institute : Kathryn Andrus

Status

Open


Clinical trials search powered by Forte Research Systems

FORTE